Erratum: Functional roles of Src and Fgr in ovarian carcinoma (Clinical Cancer Research (2011) 17 (1713-1721) DOI: 10.1158/1078-0432.CCR-10-2081);Functional roles of Src and Fgr in ovarian carcinoma

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1713-1721

  Kim, Hye Sun ^a,d   Han, Hee Dong ^a   Armaiz Pena, Guillermo N ^a   Stone, Rebecca L ^a   Nam, Eun Ji ^a,e   Lee, Jeong Won ^a,f   Shahzad, Mian M K ^a,c   Nick, Alpa M ^a   Lee, Sun Joo ^a,g   Roh, Ju Won ^a,h   Nishimura, Masato ^a   Mangala, Lingegowda S ^a,b   Bottsford Miller, Justin ^a   Gallick, Gary E ^a   Lopez Berestein, Gabriel ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NASA JOHNSON SPACE CENTER   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Catholic Kwandong University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g Konkuk University Hospital   (South Korea)

^h Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CHITOSAN; DOCETAXEL; NANOPARTICLE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; FGR GENE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SRC GENE;

EID: 79953319793     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-21-2118     Document Type: Erratum

References (30)

1. Society AC. Cancer Facts and Figures-2009. Atalnta, GA: American Cancer Society; 2009.
2. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 2002;52:216-25.
3. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906-9. (Pubitemid 39468849)
4. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609. (Pubitemid 28034534)
5. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-9. (Pubitemid 44449178)
6. Lowell CA, Fumagalli L, Berton G. Deficiency of Src family kinases p59/61hck and p58c-fgr results in defective adhesion-dependent neutrophil functions. J Cell Biol 1996;133:895-910.
7. Mocsai A, Ligeti E, Lowell CA, Berton G. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 1999;162:1120-6. (Pubitemid 29035443)
8. Suen PW, Ilic D, Caveggion E, Berton G, Damsky CH, Lowell CA. Impaired integrin-mediated signal transduction, altered cytoskeletal structure and reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 1999;112(Pt 22):4067-78. (Pubitemid 30119775)
9. Gresham HD, Dale BM, Potter JW, et al. Negative regulation of phagocytosis in murine macrophages by the Src kinase family member, Fgr. J Exp Med 2000;191:515-28.
10. Baruzzi A, Caveggion E, Berton G. Regulation of phagocyte migration and recruitment by Src-family kinases. Cell Mol Life Sci 2008;65:2175-90.
11. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61.
12. Sharp NA, Luscombe MJ, Clemens MJ. Regulation of c-fgr protooncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels. Oncogene 1989;4:1043-6. (Pubitemid 19202823)
13. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81:717-23. (Pubitemid 32466534)
14. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 2009;15:3770-80.
15. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009;101:1193-205.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. (Pubitemid 34164012)
17. Spannuth WA, Nick AM, Jennings NB, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009;124:1045-53.
18. Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22.
19. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18:185-97.
20. Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 2009;8:1027-34.
21. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9. (Pubitemid 36062670)
22. Budde RJ, Ke S, Levin VA. Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys 1994;14:171-5.
23. Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003;309:377-83. (Pubitemid 37025902)
24. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 2005;4:217-24. (Pubitemid 40340201)
25. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999;5:2164-70. (Pubitemid 29399273)
26. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9. (Pubitemid 41507982)
27. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003;9:5271-81. (Pubitemid 37413579)
28. Han HD, Song CK, Park YS, et al. A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 2008;350:27-34. (Pubitemid 351146677)
29. Seo SH, Han HD, Noh KH, Kim TW, Son SW. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis 2009;26:179-87.
30. Han HD, Nam DE, Seo DH, Kim TW, Shin BC, Choi HS. Preparation and biodegradation of thermosensitive chitosan hydrogel as a function of pH and temperature. Macromol Res 2004;12:507-11.